Sophia Genetics
SwitzerlandWho owns Sophia Genetics?
Sophia Genetics is a Swiss Biotech company, currently owned by Eurazeo since 2019 and Malakoff Humanis Innov'.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Co-held by Eurazeo and Malakoff Humanis Innov' since 2019.
- ·Average hold across 3 realized cycles: 3 years.
- ·5 distinct PE sponsors across ownership cycles.
Ownership history
5 ownership periods · co-invest detected
360 Capital Partners took Sophia Genetics public via IPO in 2021 after 7 years.
Balderton Capital took Sophia Genetics public via IPO in 2021 after 2 years.
Hitachi Ventures took SOPHiA GENETICS public via IPO in 2021 after 1 year.
More from Eurazeo Growth Fund III
Other portfolio companies in the same fund.
France
US
Germany
Spain
NetherlandsMore PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns Sophia Genetics?
Sophia Genetics is currently owned by Eurazeo and Malakoff Humanis Innov', through Eurazeo Growth Fund III, since 2019.
When did Eurazeo and 1 other acquire Sophia Genetics?
Eurazeo and 1 other acquired Sophia Genetics in 2019.
Who has owned Sophia Genetics over time?
Sophia Genetics has been through 5 private-equity ownership periods: 360 Capital Partners · via 360 Capital 2011 · 2014–2021 · (IPO); Eurazeo · via Eurazeo Growth Fund III · 2019–2021; Balderton Capital · via Balderton Capital VII · 2019–2021 · (IPO); Hitachi Ventures · via Hitachi Ventures Fund I · 2020–2021 · (IPO); Malakoff Humanis Innov' · via MH Innov'.